Nanoformulations of doxorubicin: How far have we come and where do we go from here?
Authorized Users Only
2018
Authors
Borišev, IvanaMrđanović, Jasminka Ž.
Petrović, Danijela
Seke, Mariana

Jović, Danica S.
Srđenović, Branislava U.
Latinović, Nataša
Đorđević, Aleksandar N.

Article (Published version)

© 2018 IOP Publishing Ltd
Metadata
Show full item recordAbstract
Nanotechnology, focused on discovery and development of new pharmaceutical products is known as nanopharmacology, and one research area this branch is engaged in are nanopharmaceuticals. The importance of being nano has been particularly emphasized in scientific areas dealing with nanomedicine and nanopharmaceuticals. Nanopharmaceuticals, their routes of administration, obstacles and solutions concerning their improved application and enhanced efficacy have been briefly yet comprehensively described. Cancer is one of the leading causes of death worldwide and evergrowing number of scientific research on the topic only confirms that the needs have not been completed yet and that there is a wide platform for improvement. This is undoubtedly true for nanoformulations of an anticancer drug doxorubicin, where various nanocarrriers were given an important role to reduce the drug toxicity, while the efficacy of the drug was supposed to be retained or preferably enhanced. Therefore, we present ...an interdisciplinary comprehensive overview of interdisciplinary nature on nanopharmaceuticals based on doxorubicin and its nanoformulations with valuable information concerning trends, obstacles and prospective of nanopharmaceuticals development, mode of activity of sole drug doxorubicin and its nanoformulations based on different nanocarriers, their brief descriptions of biological activity through assessing in vitro and in vivo behavior.
Keywords:
anticancer activity / doxorubicin / nanocarrier / nanodrug delivery / nanoformulation / nanopharmaceuticalsSource:
Nanotechnology, 2018, 29, 33, 332002-Funding / projects:
DOI: 10.1088/1361-6528/aac7dd
ISSN: 0957-4484; 1361-6528
PubMed: 29798934
WoS: 000434986900001
Scopus: 2-s2.0-85049009491
URI
http://stacks.iop.org/0957-4484/29/i=33/a=332002?key=crossref.4804877570e2609bf6333877ee495ab3https://vinar.vin.bg.ac.rs/handle/123456789/7751
Collections
Institution/Community
VinčaTY - JOUR AU - Borišev, Ivana AU - Mrđanović, Jasminka Ž. AU - Petrović, Danijela AU - Seke, Mariana AU - Jović, Danica S. AU - Srđenović, Branislava U. AU - Latinović, Nataša AU - Đorđević, Aleksandar N. PY - 2018 UR - http://stacks.iop.org/0957-4484/29/i=33/a=332002?key=crossref.4804877570e2609bf6333877ee495ab3 UR - https://vinar.vin.bg.ac.rs/handle/123456789/7751 AB - Nanotechnology, focused on discovery and development of new pharmaceutical products is known as nanopharmacology, and one research area this branch is engaged in are nanopharmaceuticals. The importance of being nano has been particularly emphasized in scientific areas dealing with nanomedicine and nanopharmaceuticals. Nanopharmaceuticals, their routes of administration, obstacles and solutions concerning their improved application and enhanced efficacy have been briefly yet comprehensively described. Cancer is one of the leading causes of death worldwide and evergrowing number of scientific research on the topic only confirms that the needs have not been completed yet and that there is a wide platform for improvement. This is undoubtedly true for nanoformulations of an anticancer drug doxorubicin, where various nanocarrriers were given an important role to reduce the drug toxicity, while the efficacy of the drug was supposed to be retained or preferably enhanced. Therefore, we present an interdisciplinary comprehensive overview of interdisciplinary nature on nanopharmaceuticals based on doxorubicin and its nanoformulations with valuable information concerning trends, obstacles and prospective of nanopharmaceuticals development, mode of activity of sole drug doxorubicin and its nanoformulations based on different nanocarriers, their brief descriptions of biological activity through assessing in vitro and in vivo behavior. T2 - Nanotechnology T1 - Nanoformulations of doxorubicin: How far have we come and where do we go from here? VL - 29 IS - 33 SP - 332002 DO - 10.1088/1361-6528/aac7dd ER -
@article{ author = "Borišev, Ivana and Mrđanović, Jasminka Ž. and Petrović, Danijela and Seke, Mariana and Jović, Danica S. and Srđenović, Branislava U. and Latinović, Nataša and Đorđević, Aleksandar N.", year = "2018", abstract = "Nanotechnology, focused on discovery and development of new pharmaceutical products is known as nanopharmacology, and one research area this branch is engaged in are nanopharmaceuticals. The importance of being nano has been particularly emphasized in scientific areas dealing with nanomedicine and nanopharmaceuticals. Nanopharmaceuticals, their routes of administration, obstacles and solutions concerning their improved application and enhanced efficacy have been briefly yet comprehensively described. Cancer is one of the leading causes of death worldwide and evergrowing number of scientific research on the topic only confirms that the needs have not been completed yet and that there is a wide platform for improvement. This is undoubtedly true for nanoformulations of an anticancer drug doxorubicin, where various nanocarrriers were given an important role to reduce the drug toxicity, while the efficacy of the drug was supposed to be retained or preferably enhanced. Therefore, we present an interdisciplinary comprehensive overview of interdisciplinary nature on nanopharmaceuticals based on doxorubicin and its nanoformulations with valuable information concerning trends, obstacles and prospective of nanopharmaceuticals development, mode of activity of sole drug doxorubicin and its nanoformulations based on different nanocarriers, their brief descriptions of biological activity through assessing in vitro and in vivo behavior.", journal = "Nanotechnology", title = "Nanoformulations of doxorubicin: How far have we come and where do we go from here?", volume = "29", number = "33", pages = "332002", doi = "10.1088/1361-6528/aac7dd" }
Borišev, I., Mrđanović, J. Ž., Petrović, D., Seke, M., Jović, D. S., Srđenović, B. U., Latinović, N.,& Đorđević, A. N.. (2018). Nanoformulations of doxorubicin: How far have we come and where do we go from here?. in Nanotechnology, 29(33), 332002. https://doi.org/10.1088/1361-6528/aac7dd
Borišev I, Mrđanović JŽ, Petrović D, Seke M, Jović DS, Srđenović BU, Latinović N, Đorđević AN. Nanoformulations of doxorubicin: How far have we come and where do we go from here?. in Nanotechnology. 2018;29(33):332002. doi:10.1088/1361-6528/aac7dd .
Borišev, Ivana, Mrđanović, Jasminka Ž., Petrović, Danijela, Seke, Mariana, Jović, Danica S., Srđenović, Branislava U., Latinović, Nataša, Đorđević, Aleksandar N., "Nanoformulations of doxorubicin: How far have we come and where do we go from here?" in Nanotechnology, 29, no. 33 (2018):332002, https://doi.org/10.1088/1361-6528/aac7dd . .